Evinacumab reduces EU apheresis eligibility in patients with homozygous familial hypercholesterolemia

Background and Aims: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder associated with impaired low-density lipoprotein cholesterol (LDL-C) clearance from the circulation, leading to extremely elevated LDL-C levels and resulting in increased cardiovascular events and premature mortality. Evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, has demonstrated LDL-C reductions of approximately 50% in patients with HoFH. This post-hoc analysis assessed the effect of evinacumab on the change in apheresis eligibility based on predefined EU apheresis criteria in patients with HoFH.